A detailed history of Callan Capital, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Callan Capital, LLC holds 6,483 shares of ABBV stock, worth $1.1 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
6,483
Previous 6,063 6.93%
Holding current value
$1.1 Million
Previous $1.04 Million 23.2%
% of portfolio
0.09%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$163.84 - $199.33 $68,812 - $83,718
420 Added 6.93%
6,483 $1.28 Million
Q2 2024

Aug 12, 2024

BUY
$154.79 - $180.76 $10,216 - $11,930
66 Added 1.1%
6,063 $1.04 Million
Q1 2024

Oct 22, 2024

SELL
$159.82 - $182.1 $10,548 - $12,018
-66 Reduced 1.09%
5,997 $1.09 Million
Q1 2024

May 03, 2024

BUY
$159.82 - $182.1 $121,303 - $138,213
759 Added 14.49%
5,997 $1.09 Million
Q4 2023

Feb 02, 2024

SELL
$137.6 - $154.97 $79,395 - $89,417
-577 Reduced 9.92%
5,238 $811,000
Q3 2023

Nov 06, 2023

BUY
$133.59 - $154.65 $168,323 - $194,859
1,260 Added 27.66%
5,815 $866,000
Q2 2023

Aug 04, 2023

BUY
$132.51 - $164.9 $80,433 - $100,094
607 Added 15.37%
4,555 $613,000
Q1 2023

Jun 13, 2023

SELL
$144.61 - $166.54 $156,323 - $180,029
-1,081 Reduced 21.5%
3,948 $629,000
Q1 2023

May 08, 2023

SELL
$144.61 - $166.54 $156,323 - $180,029
-1,081 Reduced 21.5%
3,948 $629,000
Q4 2022

Jun 13, 2023

BUY
$138.31 - $165.87 $149,513 - $179,305
1,081 Added 27.38%
5,029 $813,000
Q4 2022

Feb 13, 2023

BUY
$138.31 - $165.87 $337,614 - $404,888
2,441 Added 94.32%
5,029 $813,000
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $347,335 - $398,370
2,588 New
2,588 $347,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $300B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Callan Capital, LLC Portfolio

Follow Callan Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Callan Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Callan Capital, LLC with notifications on news.